Trial reportThe Journal of allergy and clinical immunology2013
Sublingual immunotherapy for peanut allergy: a randomized, double-blind, placebo-controlled multicenter trial.
Trial report in The Journal of allergy and clinical immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00580606 (Sublingual Immunotherapy for Peanut Allergy), which is not on this map. Cited by 103 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Sublingual Immunotherapy for Peanut Allergy: A Randomized, Double-Blind, Placebo-Controlled, Phase I/II Pilot Study With a Whole Peanut Extract
Who cites it
103 citing papers in PubMed, 2 syntheses or guidelines pooled it, 306 citations in OpenAlex.
- Allergen immunotherapy and/or biologicals for IgE-mediated food allergy: A systematic review and meta-analysis.Allergy · 2022Pooled it
- Immunotherapy (oral and sublingual) for food allergy to fruits.The Cochrane database of systematic reviews · 2015Pooled it
- Desensitization and remission after peanut sublingual immunotherapy in 1- to 4-year-old peanut-allergic children: A randomized, placebo-controlled trial.The Journal of allergy and clinical immunology · 2024Trial
- Open-label study of the efficacy, safety, and durability of peanut sublingual immunotherapy in peanut-allergic children.The Journal of allergy and clinical immunology · 2023Trial
- Epicutaneous immunotherapy for treatment of peanut allergy: Follow-up from the Consortium for Food Allergy Research.The Journal of allergy and clinical immunology · 2021Trial
- Sustained successful peanut oral immunotherapy associated with low basophil activation and peanut-specific IgE.The Journal of allergy and clinical immunology · 2020Trial
- Long-term sublingual immunotherapy for peanut allergy in children: Clinical and immunologic evidence of desensitization.The Journal of allergy and clinical immunology · 2019Trial
- Trial
- Epicutaneous immunotherapy for the treatment of peanut allergy in children and young adults.The Journal of allergy and clinical immunology · 2017Trial
- Food-specific sublingual immunotherapy is well tolerated and safe in healthy dogs: a blind, randomized, placebo-controlled study.BMC veterinary research · 2017Trial
- Long-term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy.The Journal of allergy and clinical immunology · 2016Trial
- Utility of component analyses in subjects undergoing sublingual immunotherapy for peanut allergy.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2016Trial
- Safety, clinical, and immunologic efficacy of a Chinese herbal medicine (Food Allergy Herbal Formula-2) for food allergy.The Journal of allergy and clinical immunology · 2015Trial
- Sublingual immunotherapy for peanut allergy: Long-term follow-up of a randomized multicenter trial.The Journal of allergy and clinical immunology · 2015Trial
- A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy.The Journal of allergy and clinical immunology · 2015Trial
- Omalizumab and Oral Immunotherapy in IgE-Mediated Food Allergy in Children: A Systematic Review and a Meta-Analysis.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Anti-IgE therapy versus allergen-specific immunotherapy for food allergy: weighing the pros and cons.Frontiers in immunology · 2025Review
- Dietary fiber pectin alters the gut microbiota and diminishes the inflammatory immune responses in an experimental peach allergy mouse model.Scientific reports · 2024Article
- Advancements in food allergen immunotherapy: improving quality of life and reducing risks.Clinical and experimental pediatrics · 2024Article
- A review of sublingual immunotherapy for treatment of peanut allergy.Journal of food allergy · 2024Article
43 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 7 institutions in 1 country.
Funding
Abstract
backgroundThere are presently no available therapeutic options for patients with peanut allergy.
objectiveWe sought to investigate the safety, efficacy, and immunologic effects of peanut sublingual immunotherapy (SLIT).
methodsAfter a baseline oral food challenge (OFC) of up to 2 g of peanut powder (approximately 50% protein; median successfully consumed dose [SCD], 46 mg), 40 subjects, aged 12 to 37 years (median, 15 years), were randomized 1:1 across 5 sites to daily peanut or placebo SLIT. A 5-g OFC was performed after 44 weeks, followed by unblinding; placebo-treated subjects then crossed over to higher dose peanut SLIT, followed by a subsequent crossover Week 44 5-g OFC. Week 44 OFCs from both groups were compared with baseline OFCs; subjects successfully consuming 5 g or at least 10-fold more peanut powder than the baseline OFC threshold were considered responders.
resultsAfter 44 weeks of SLIT, 14 (70%) of 20 subjects receiving peanut SLIT were responders compared with 3 (15%) of 20 subjects receiving placebo (P < .001). In peanut SLIT responders, median SCD increased from 3.5 to 496 mg. After 68 weeks of SLIT, median SCD significantly increased to 996 mg (compared with Week 44, P = .05). The median SCD at the Week 44 Crossover OFC was significantly higher than baseline (603 vs 71 mg, P = .02). Seven (44%) of 16 crossover subjects were responders; median SCD increased from 21 to 496 mg among responders. Of 10,855 peanut doses through the Week 44 OFCs, 63.1% were symptom free; excluding oral-pharyngeal symptoms, 95.2% were symptom free.
conclusionsPeanut SLIT safely induced a modest level of desensitization in a majority of subjects compared with placebo. Longer duration of therapy showed statistically significant increases in the SCD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.